Therefore, we conducted a comprehensive survey of patients with AML with BCR::ABL1 using nationwide registry data and additional questionnaires to clarify how TKI treatment before and after allo‐HCT, MRD status, BCR::ABL1 subtype, and additional cytogenetic abnormalities influence transplant outcomes. This evidence concerns the gene BCR and acute myeloid leukemia.